Journal article
Acetyltransferases (HATs) as Targets for Neurological Therapeutics
Neurotherapeutics, Vol.10(4), pp.568-588
10/01/2013
DOI: 10.1007/s13311-013-0204-7
PMCID: PMC3805875
PMID: 24006237
Abstract
The acetylation of histone and non-histone proteins controls a great deal of cellular functions, thereby affecting the entire organism, including the brain. Acetylation modifications are mediated through histone acetyltransferases (HAT) and deacetylases (HDAC), and the balance of these enzymes regulates neuronal homeostasis, maintaining the pre-existing acetyl marks responsible for the global chromatin structure, as well as regulating specific dynamic acetyl marks that respond to changes and facilitate neurons to encode and strengthen long-term events in the brain circuitry (e. g., memory formation). Unfortunately, the dysfunction of these finely-tuned regulations might lead to pathological conditions, and the deregulation of the HAT/HDAC balance has been implicated in neurological disorders. During the last decade, research has focused on HDAC inhibitors that induce a histone hyperacetylated state to compensate acetylation deficits. The use of these inhibitors as a therapeutic option was efficient in several animal models of neurological disorders. The elaboration of new cell-permeant HAT activators opens a new era of research on acetylation regulation. Although pathological animal models have not been tested yet, HAT activator molecules have already proven to be beneficial in ameliorating brain functions associated with learning and memory, and adult neurogenesis in wild-type animals. Thus, HAT activator molecules contribute to an exciting area of research.
Details
- Title: Subtitle
- Acetyltransferases (HATs) as Targets for Neurological Therapeutics
- Creators
- Anne Schneider - Laboratoire de Neurosciences Cognitives et AdaptativesSnehajyoti Chatterjee - Laboratoire de Neurosciences Cognitives et AdaptativesOlivier Bousiges - Laboratoire de Neurosciences Cognitives et AdaptativesB. Ruthrotha Selvi - Jawaharlal Nehru Centre for Advanced Scientific ResearchAmrutha Swaminathan - Jawaharlal Nehru Centre for Advanced Scientific ResearchRaphaelle Cassel - Laboratoire de Neurosciences Cognitives et AdaptativesFrederic Blanc - University of StrasbourgTapas K. Kundu - Jawaharlal Nehru Centre for Advanced Scientific ResearchAnne-Laurence Boutillier - Laboratoire de Neurosciences Cognitives et Adaptatives
- Resource Type
- Journal article
- Publication Details
- Neurotherapeutics, Vol.10(4), pp.568-588
- DOI
- 10.1007/s13311-013-0204-7
- PMID
- 24006237
- PMCID
- PMC3805875
- NLM abbreviation
- Neurotherapeutics
- ISSN
- 1933-7213
- eISSN
- 1878-7479
- Publisher
- Springer Nature
- Number of pages
- 21
- Grant note
- Pfizer ANR-12-MALZ-0002 / Agence Nationale pour la Recherche; French National Research Agency (ANR) TEVA Neurosciences; Teva Pharmaceutical Industries Bayer Schering; Bayer AG Department of Biotechnology Alsace Alzheimer 67 association Novartis Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR); Department of Science & Technology (India) Department of Science and Technology through the government of India Lundbeck; Lundbeck Corporation French government Merck Serono; Merck & Company 4803-3 / Indo-French Centre for the Promotion of Advanced Research (IFCPAR/CEFIPRA) Centre National de la Recherche Scientifique (CNRS) University of Strasbourg DBT/CSH/GIA/1752 / Government of India ANR-12-MALZ-0002-01 / Agence Nationale de la Recherche; French National Research Agency (ANR); European Commission Council for Scientific and Industrial Research; Council of Scientific & Industrial Research (CSIR) - India
- Language
- English
- Date published
- 10/01/2013
- Academic Unit
- Iowa Neuroscience Institute; Neuroscience and Pharmacology
- Record Identifier
- 9984303741502771
Metrics
18 Record Views